213 related articles for article (PubMed ID: 35264436)
1. Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy.
Anderson KG; Oda SK; Bates BM; Burnett MG; Rodgers Suarez M; Ruskin SL; Greenberg PD
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264436
[TBL] [Abstract][Full Text] [Related]
2. A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy.
Oda SK; Anderson KG; Ravikumar P; Bonson P; Garcia NM; Jenkins CM; Zhuang S; Daman AW; Chiu EY; Bates BM; Greenberg PD
J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32860705
[TBL] [Abstract][Full Text] [Related]
3. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD
Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659
[TBL] [Abstract][Full Text] [Related]
4. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.
Yamamoto TN; Lee PH; Vodnala SK; Gurusamy D; Kishton RJ; Yu Z; Eidizadeh A; Eil R; Fioravanti J; Gattinoni L; Kochenderfer JN; Fry TJ; Aksoy BA; Hammerbacher JE; Cruz AC; Siegel RM; Restifo NP; Klebanoff CA
J Clin Invest; 2019 Feb; 129(4):1551-1565. PubMed ID: 30694219
[TBL] [Abstract][Full Text] [Related]
5. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
[TBL] [Abstract][Full Text] [Related]
6. Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models.
Schoutrop E; Poiret T; El-Serafi I; Zhao Y; He R; Moter A; Henriksson J; Hassan M; Magalhaes I; Mattsson J
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746513
[TBL] [Abstract][Full Text] [Related]
7. Mesothelin-Specific CAR T Cells Target Ovarian Cancer.
Schoutrop E; El-Serafi I; Poiret T; Zhao Y; Gultekin O; He R; Moyano-Galceran L; Carlson JW; Lehti K; Hassan M; Magalhaes I; Mattsson J
Cancer Res; 2021 Jun; 81(11):3022-3035. PubMed ID: 33795251
[TBL] [Abstract][Full Text] [Related]
8. Ligand-based adoptive T cell targeting CA125 in ovarian cancer.
Zhao H; Wu L; Dai J; Sun K; Zi Z; Guan J; Zhang L
J Transl Med; 2023 Sep; 21(1):596. PubMed ID: 37670338
[TBL] [Abstract][Full Text] [Related]
9. Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid Tumors.
Bajgain P; Torres Chavez AG; Balasubramanian K; Fleckenstein L; Lulla P; Heslop HE; Vera J; Leen AM
Cancer Immunol Res; 2022 Nov; 10(11):1370-1385. PubMed ID: 36122411
[TBL] [Abstract][Full Text] [Related]
10. Mesothelin-targeting T cells bearing a novel T cell receptor fusion construct (TRuC) exhibit potent antitumor efficacy against solid tumors.
Ding J; Guyette S; Schrand B; Geirut J; Horton H; Guo G; Delgoffe G; Menk A; Baeuerle PA; Hofmeister R; Tighe R
Oncoimmunology; 2023; 12(1):2182058. PubMed ID: 36875551
[TBL] [Abstract][Full Text] [Related]
11. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
[TBL] [Abstract][Full Text] [Related]
12. Distinct regulation of T-cell death by CD28 depending on both its aggregation and T-cell receptor triggering: a role for Fas-FasL.
Collette Y; Benziane A; Razanajaona D; Olive D
Blood; 1998 Aug; 92(4):1350-63. PubMed ID: 9694724
[TBL] [Abstract][Full Text] [Related]
13. Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer.
Li K; Xu J; Wang J; Lu C; Dai Y; Dai Q; Zhang W; Xu C; Wu S; Kang Y
Cancer Immunol Immunother; 2023 Apr; 72(4):917-928. PubMed ID: 36166071
[TBL] [Abstract][Full Text] [Related]
14. Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer.
Guo J; Zeng X; Zhu Y; Yang D; Zhao X
J Transl Med; 2024 Apr; 22(1):367. PubMed ID: 38637885
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism.
Zhu J; Petit PF; Van den Eynde BJ
Cancer Immunol Immunother; 2019 May; 68(5):835-847. PubMed ID: 30406374
[TBL] [Abstract][Full Text] [Related]
16. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.
Dotti G; Savoldo B; Pule M; Straathof KC; Biagi E; Yvon E; Vigouroux S; Brenner MK; Rooney CM
Blood; 2005 Jun; 105(12):4677-84. PubMed ID: 15713795
[TBL] [Abstract][Full Text] [Related]
17. Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor.
McCarthy D; Lofgren M; Watt A; Horton H; Kieffer-Kwon P; Ding J; Kobold S; Baeuerle PA; Hofmeister R; Gutierrez DA; Tighe R
Cancer Immunol Immunother; 2023 Dec; 72(12):4195-4207. PubMed ID: 37848682
[TBL] [Abstract][Full Text] [Related]
18. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
[TBL] [Abstract][Full Text] [Related]
19. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
[TBL] [Abstract][Full Text] [Related]
20. Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells.
Gopalan B; Litvak A; Sharma S; Mhashilkar AM; Chada S; Ramesh R
Cancer Res; 2005 Apr; 65(8):3017-24. PubMed ID: 15833826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
